Business Wire

Fast Vote Count Surprises and Delights Argentina

28.10.2019 21:42:00 EET | Business Wire | Press release

Share

Argentina processed election results with record-breaking speed during its general elections thanks to the new system implemented in partnership with technology company Smartmatic. The vote was held on October 27.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005666/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Telegram processing rates on election night, 2015 vs. 2019. (Photo: Business Wire)

Only three hours after voting ended, 70.48% of the tallying reports (called “telegrams” in Argentina) had been digitized, securely transmitted and uploaded into the system. By midnight, 96.08% of telegrams were processed.

Election observers representing the political parties closely monitored the entire process. The high level of transparency and speed with which the results were processed and published allowed the main candidates to publicly accept the outcomes shortly after results were announced.

“We are honored to have supported Argentine authorities for this important election by deploying Smartmatic’s unmatched technology. We were able to facilitate fast, accurate results that gave peace of mind to political parties and the country in general,” said Antonio Mugica, CEO of Smartmatic.

According to information released by election authorities, voter participation exceeded 80%. Voters chose among four candidates for head of government and six formulas for president and vice president. In eight provinces, 72 candidates vied for senate seats and 595 candidates competed to become deputies at the national level.

Smartmatic provided secure technology both for the digitation and transmission of telegrams, and for the consolidation and publication of results. Just as in the primaries held in August, telegrams were transmitted directly from over 10,000 voting centers to two consolidation centers. Approximately 1,700 operators at the consolidation centers transcribed and loaded into the system the information contained in the telegrams.

"Because of the speed and accuracy with which results were published, misinformation about the technology that had been widely distributed across social media and other news outlets fell flat and was easily discredited. Argentines today welcomed the innovations introduced by the authorities that make elections more efficient and more transparent," added Mugica.

Smartmatic participated in Argentina’s 2019 election cycle after winning two public bids in which international election technology companies competed.

It is anticipated that, as in the primaries, the provisional results will be an accurate reflection of the final vote count. In August, the difference between the provisional and final results was less than 1% in each of the Argentine provinces.

About Smartmatic

Smartmatic specializes in the design and deployment of election system technologies. As the global leader in providing secure, transparent, verifiable voting systems, Smartmatic is setting the standard for election integrity worldwide including encrypted results transmission, paper ballot back-up, extensive auditing and the first use of blockchain technology to secure online voting. Additional information about Smartmatic can be found at: www.smartmatic.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Smartmatic
Mrs. Samira Saba, +1-561-862-0747
Marketing and Communications Director
Communications@smartmatic.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye